Tirzepatide ni imiti yubuvanganzo yerekana intambwe ikomeye mu kuvura diyabete yo mu bwoko bwa 2 n'umubyibuho ukabije. Nibintu byambere bibiri bya agonist ya glucose iterwa na insulineotropique polypeptide (GIP) hamwe na glucagon imeze nka peptide-1 (GLP-1). Ubu buryo bwihariye bwibikorwa butandukanya nubuvuzi buriho kandi butuma ingaruka zikomeye haba kugenzura glucose yamaraso no kugabanya ibiro.
Mugukoresha reseptor ya GIP na GLP-1, Tirzepatide yongerera imisemburo ya insuline no kumva, igabanya ururenda rwa glucagon, igabanya umuvuduko wa gastrica, kandi igabanya ubushake bwo kurya.
Tirzepatide ikoreshwa nk'inshinge imwe mu cyumweru, inshinge zidasanzwe mu bigeragezo byo kwa muganga. Itezimbere cyane glycemic igenzura kandi igabanya uburemere bwumubiri, akenshi irenga imikorere yimiti iboneka ubu. Byongeye kandi, inyungu z'umutima-mitsi zishobora kugaragara.
Ingaruka zikunze kugaragara ni gastrointestinal, harimo isesemi, impiswi, no kuruka, ubusanzwe byoroheje bikabije bikabije kandi bikunda kugabanuka mugihe runaka.
Muri rusange, iterambere rya Tirzepatide ryerekana imipaka mishya mu kuvura indwara ziterwa na metabolike, itanga igikoresho gikomeye cyo kurwanya diyabete n'umubyibuho ukabije.
Igihe cyo kohereza: Nzeri-01-2025